Loading data
GSKNYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 45.15 bn USD | 40.08 bn USD | 39.85 bn USD | 36.25 bn USD | 46.76 bn USD |
| Cost of revenue | 9.91 bn USD | 8.78 bn USD | 8.71 bn USD | 9.52 bn USD | 12.71 bn USD |
| Gross profit | 35.24 bn USD | 31.29 bn USD | 31.13 bn USD | 26.72 bn USD | 34.05 bn USD |
| Research and development expense | 10.13 bn USD | 8.01 bn USD | 7.93 bn USD | 6.61 bn USD | 7.15 bn USD |
| Selling, general and administrative expense | 21.6 bn USD | 18.75 bn USD | 18.91 bn USD | 15.93 bn USD | 20.85 bn USD |
| Operating profit after depreciation | 10.8 bn USD | 9.62 bn USD | 9.54 bn USD | 8.42 bn USD | 10.27 bn USD |
| Operating profit before depreciation | 13.64 bn USD | 12.55 bn USD | 12.22 bn USD | 10.8 bn USD | 13.2 bn USD |
| EBIT | 10.8 bn USD | 9.62 bn USD | 9.54 bn USD | 8.42 bn USD | 10.27 bn USD |
| EBITDA | 13.64 bn USD | 12.55 bn USD | 12.22 bn USD | 10.8 bn USD | 13.2 bn USD |
| Interest expense | 897.72 m USD | 806.22 m USD | 987.2 m USD | 1.03 bn USD | 1.06 bn USD |
| Profit before tax | 9.96 bn USD | 4.35 bn USD | 7.72 bn USD | 6.78 bn USD | 7.37 bn USD |
| Income tax expense | 1.5 bn USD | 658.5 m USD | 962.99 m USD | 851.86 m USD | 468.52 m USD |
| Income before extraordinary items | 7.69 bn USD | 3.22 bn USD | 6.28 bn USD | 5.38 bn USD | 5.94 bn USD |
| Net income (reported basis) | 7.69 bn USD | 3.22 bn USD | 6.28 bn USD | 18.02 bn USD | 5.94 bn USD |
| Basic EPS including extraordinary items | 3.8 USD/share | 1.58 USD/share | 3.1 USD/share | 8.95 USD/share | 2.37 USD/share |
| Diluted EPS including extraordinary items | 3.74 USD/share | 1.55 USD/share | 3.06 USD/share | 8.82 USD/share | 2.34 USD/share |
| Common dividends | 3.45 bn USD | 3.06 bn USD | 2.86 bn USD | 4.18 bn USD | 5.42 bn USD |
| Total dividends | 3.45 bn USD | 3.06 bn USD | 2.86 bn USD | 4.18 bn USD | 5.42 bn USD |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.